Alector, Inc.
ALEC Nasdaq Biological Products, (No Diagnostic Substances) 金融 FY2017–FY2025
最新收盘价 · 2026年10月23日
$1.83
0.0%Alector, Inc. 的业务
暂无业务介绍。
- 法定名称
- Alector, Inc.
- 财年结束日
- 2025年12月31日
- 最新年报
- 10-K · 2026年2月25日
- 登记号 · CIK
- 0001193125-26-071593
0001653087
营收与利润率
Alector, Inc. 在 2025 财年 营收为 $21.0M,同比下降 79.1%。
净利润与每股收益
亏损期间以红色显示。
资本回报率
税后营业利润占投入业务资金(债务加股东权益减现金)的比例。
现金流
2025 财年 的自由现金流为 −$184M,占营收的 −874.7%。 经营现金流减资本支出。
股息、回购与股数
Alector, Inc. 在 2025 财年 向股东返还 —。 稀释股数增加 6.6%。
资产负债表
现金、债务以及显示 Alector, Inc. 承担债务能力的指标。
| 财年末 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| 现金及短期投资 | $735M | $713M | $549M | $413M | $256M |
| 债务(含融资租赁) | — | — | $0.0M | $10.0M | $10.4M |
| 债务 / 股东权益 | — | — | 0.0x | 0.1x | 0.3x |
| 流动比率 | 5.4x | 7.7x | 3.2x | 3.4x | 3.8x |
| 速动比率 | 5.4x | 7.7x | 3.2x | 3.4x | 3.8x |
| 总资产 | $815M | $788M | $622M | $468M | $293M |
| 总负债 | $514M | $573M | $488M | $342M | $263M |
| 股东权益 | $301M | $214M | $134M | $127M | $30.6M |
| 净债务 (− = 净现金) | — | — | −$549M | −$403M | −$246M |
内部人交易
高管、董事和持股超过 10% 的股东在公开市场的买卖,数据来自 Form 4 申报。“计划”表示依据事先制定的 Rule 10b5-1 计划进行的交易。
买入(12 个月)
$0.0M
0 名内部人士
卖出(12 个月)
$0.0M
0 名内部人士
卖出中按计划执行的比例
—
$0.0M
过去 12 个月没有公开市场的内部人交易。
Piotroski F 分数
关于盈利能力、融资和效率的九项通过/未通过测试。8–9 为强,0–2 为弱。
| 测试项 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| 净利润为正 | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| 经营现金流为正 | ✕ | ✓ | ✕ | ✕ | ✓ | ✕ | ✕ | ✕ | ✕ |
| 资产回报率上升 | — | — | ✕ | ✕ | ✓ | ✕ | ✕ | ✕ | ✕ |
| 经营现金流高于净利润 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✕ | ✕ | ✕ |
| 债务相对资产下降 | — | — | — | — | — | — | — | ✕ | ✕ |
| 流动比率上升 | — | — | ✕ | ✓ | ✕ | ✓ | ✕ | ✓ | ✓ |
| 股数未增加 | — | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| 毛利率上升 | — | — | — | — | — | — | — | — | — |
| 营收相对资产上升 | — | — | ✕ | ✕ | ✓ | ✕ | ✕ | ✓ | ✕ |
| F 分数 | — / 3 | — / 4 | 1 / 7 | 2 / 7 | 4 / 7 | 2 / 7 | 0 / 7 | 2 / 8 | 1 / 8 |
| 应计比率 | — | −58.3% | −1.7% | −5.2% | −51.4% | −14.1% | 7.6% | 20.3% | 10.8% |
| Altman Z'' | — | 2.23 | 1.97 | 0.60 | 3.43 | 2.09 | −0.98 | −3.26 | −9.85 |
9 年数据
金额单位为 USD。将鼠标悬停在指标名称上可查看定义。
| 财年 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| 利润表 | |||||||||
| 营收 | $3.7M | $27.7M | $21.2M | $21.1M | $207M | $134M | $97.1M | $101M | $21.0M |
| 研发支出 | $29.9M | $73.0M | $101M | $157M | $189M | $210M | $192M | $186M | $123M |
| 营业利润 | −$32.7M | −$57.3M | −$114M | −$195M | −$37.4M | −$138M | −$152M | −$145M | −$156M |
| 税前利润 | — | — | — | −$190M | −$36.3M | −$130M | −$125M | −$119M | −$143M |
| 所得税 | — | — | $0.0M | $0.0M | $0.0M | $3.3M | $5.2M | $0.1M | $0.2M |
| 净利润 | −$32.5M | −$52.2M | −$105M | −$190M | −$36.3M | −$133M | −$130M | −$119M | −$143M |
| 稀释每股收益 | −$3.55 | −$4.62 | −$1.71 | −$2.45 | −$0.45 | −$1.62 | −$1.56 | −$1.23 | −$1.39 |
| 稀释股数 | 0.01B | 0.01B | 0.06B | 0.08B | 0.08B | 0.08B | 0.08B | 0.10B | 0.10B |
| 现金流 | |||||||||
| 经营现金流 | −$17.8M | $127M | −$99.3M | −$167M | $299M | −$20.3M | −$184M | −$230M | −$184M |
| 资本支出 | $0.8M | $1.9M | $15.3M | $5.0M | $3.2M | $4.1M | $2.4M | $1.3M | $0.0M |
| 自由现金流 | −$18.6M | $126M | −$115M | −$172M | $295M | −$24.4M | −$187M | −$231M | −$184M |
| 折旧与摊销 | $0.7M | $1.0M | $3.8M | $5.9M | $6.3M | $5.7M | $5.7M | $5.4M | $5.7M |
| 股权激励 | $5.4M | $6.9M | $16.3M | $30.5M | $40.8M | $46.1M | $42.8M | $39.5M | $26.7M |
| 资产负债表 | |||||||||
| 现金及短期投资 | $32.5M | $290M | $353M | $413M | $735M | $713M | $549M | $413M | $256M |
| 总债务 | — | — | — | — | — | — | $0.0M | $10.0M | $10.4M |
| 流动资产 | — | $293M | $357M | $422M | $750M | $726M | $566M | $425M | $266M |
| 流动负债 | — | $47.9M | $62.0M | $68.1M | $140M | $93.8M | $178M | $125M | $69.5M |
| 固定资产净额 | — | $10.9M | $33.9M | $30.2M | $27.3M | $25.5M | $21.9M | $17.1M | $10.8M |
| 总资产 | — | $308M | $422M | $488M | $815M | $788M | $622M | $468M | $293M |
| 总负债 | — | $195M | $227M | $221M | $514M | $573M | $488M | $342M | $263M |
| 股东权益 | −$52.0M | −$97.4M | $195M | $268M | $301M | $214M | $134M | $127M | $30.6M |
| 利润率 | |||||||||
| 营业利润率 | −874.9% | −207.0% | −539.2% | −925.1% | −18.0% | −103.2% | −156.3% | −144.2% | −741.3% |
| EBITDA 利润率 | −856.7% | −203.3% | −521.4% | −897.3% | −15.0% | −98.9% | −150.4% | −138.8% | −714.1% |
| 净利率 | −869.6% | −188.8% | −496.7% | −901.6% | −17.5% | −99.8% | −134.3% | −118.4% | −679.2% |
| 自由现金流利润率 | −497.2% | 453.7% | −540.0% | −814.1% | 142.6% | −18.3% | −192.1% | −229.9% | −874.7% |
| 回报率 | |||||||||
| 已动用资本回报率 | — | −22.0% | −31.8% | −46.5% | −5.5% | −19.9% | −34.2% | −42.2% | −69.7% |
| 股本回报率 | — | — | −216.5% | −82.3% | −12.8% | −51.8% | −74.8% | −91.2% | −181.6% |
| 资产回报率 | — | −16.9% | −28.9% | −41.8% | −5.6% | −16.6% | −18.5% | −21.8% | −37.5% |
| 有形股本回报率 | — | — | −54.1% | −71.1% | −12.1% | −62.2% | −97.2% | −93.9% | −466.3% |
| 增长 | |||||||||
| 营收增长 | — | 641.0% | −23.3% | −0.6% | 881.5% | −35.5% | −27.3% | 3.6% | −79.1% |
| 自由现金流增长 | — | — | −191.2% | — | — | −108.3% | — | — | — |
| 股数变化 | — | 23.6% | 446.2% | 26.0% | 3.4% | 2.6% | 1.5% | 15.4% | 6.6% |
| 财务健康 | |||||||||
| 债务 / 股东权益 | — | — | — | — | — | — | 0.0x | 0.1x | 0.3x |
| 流动比率 | — | 6.1x | 5.8x | 6.2x | 5.4x | 7.7x | 3.2x | 3.4x | 3.8x |
| 速动比率 | — | 6.1x | 5.8x | 6.2x | 5.4x | 7.7x | 3.2x | 3.4x | 3.8x |
| 资本配置 | |||||||||
| 资本支出 / 营收 | 21.4% | 6.8% | 71.9% | 23.9% | 1.6% | 3.1% | 2.5% | 1.2% | 0.2% |
| 股权激励 / 营收 | 143.3% | 25.0% | 76.7% | 144.7% | 19.7% | 34.5% | 44.1% | 39.2% | 126.7% |
| 质量评分 | |||||||||
| Piotroski F 分数 | — | — | 1.0 | 2.0 | 4.0 | 2.0 | 0.0 | 2.0 | 1.0 |
| Altman Z'' | — | 2.2 | 2.0 | 0.6 | 3.4 | 2.1 | −1.0 | −3.3 | −9.9 |
| 应计比率 | — | −58.3% | −1.7% | −5.2% | −51.4% | −14.1% | 7.6% | 20.3% | 10.8% |
来源:SEC EDGAR XBRL 文件 (CIK 0001653087). 数据更新于 2026年10月24日。 第四季度数据为全年减去前九个月。 仅供参考,不构成投资建议。依赖任何数字前,请核对原始文件。
